King Luther Capital Management Corp boosted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 11.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 78,605 shares of the company’s stock after purchasing an additional 8,215 shares during the quarter. King Luther Capital Management Corp owned about 0.20% of Omnicell worth $5,652,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Bank of Montreal Can purchased a new stake in shares of Omnicell during the second quarter valued at approximately $102,000. Stone Ridge Asset Management LLC purchased a new stake in Omnicell in the third quarter worth approximately $202,000. Everence Capital Management Inc. purchased a new stake in Omnicell in the third quarter worth approximately $204,000. Ibex Investors LLC purchased a new stake in Omnicell in the third quarter worth approximately $209,000. Finally, Evanston Investments Inc. dba Evanston Advisors purchased a new stake in Omnicell in the third quarter worth approximately $216,000.
Shares of OMCL stock opened at $69.83 on Friday. Omnicell, Inc. has a 12-month low of $39.75 and a 12-month high of $79.48. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.32 and a current ratio of 1.78. The company has a market capitalization of $2.80 billion, a P/E ratio of 387.94, a P/E/G ratio of 4.22 and a beta of 0.99.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 25th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.40 by $0.09. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. The company had revenue of $204.27 million for the quarter, compared to analysts’ expectations of $203.48 million. As a group, equities analysts predict that Omnicell, Inc. will post 1.42 EPS for the current year.
In other Omnicell news, CFO Peter J. Kuipers sold 5,574 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $68.87, for a total value of $383,881.38. Following the transaction, the chief financial officer now directly owns 51,542 shares in the company, valued at $3,549,697.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James T. Judson sold 2,443 shares of the stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $70.67, for a total transaction of $172,646.81. Following the completion of the transaction, the director now owns 24,952 shares in the company, valued at $1,763,357.84. The disclosure for this sale can be found here. Insiders sold 19,267 shares of company stock worth $1,309,116 over the last quarter. Insiders own 3.71% of the company’s stock.
Several brokerages recently issued reports on OMCL. Oppenheimer raised their target price on shares of Omnicell to $86.00 and gave the stock an “outperform” rating in a report on Friday. Cantor Fitzgerald restated an “overweight” rating and issued a $80.00 target price (up previously from $70.00) on shares of Omnicell in a report on Thursday. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 22nd. Zacks Investment Research restated a “strong-buy” rating and issued a $78.00 target price on shares of Omnicell in a report on Wednesday, November 14th. Finally, Wells Fargo & Co raised their target price on shares of Omnicell from $59.00 to $61.00 and gave the stock a “market perform” rating in a report on Monday, October 29th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Omnicell has an average rating of “Buy” and a consensus price target of $73.75.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Recommended Story: What is a put option?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.